Ligand-Coated Gas Microvesicles for Stable Cell Separation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing methods for isolating cells using gas encapsulated microvesicles face challenges such as microvesicle aggregation and destabilization due to high ligand density, which complicates the separation process.
Innovation Solution
A suspension of gas-filled microvesicles is formulated with a stabilizing envelope comprising a phospholipid, a first pegylated phospholipid with a reactive moiety, and a second pegylated phospholipid, with controlled ligand density to minimize aggregation, using a manufacturing process that includes an aqueous-organic emulsion, coupling, and lyophilization.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If high ligand density is used on microvesicles, then cell binding efficiency increases, but microvesicle aggregation occurs
Solution Approach 1:
The patent applies parameter changes by precisely controlling the ligand density parameter to fall within the range of 100-10,000 ligands per microvesicle, and by adjusting the molar ratios of phospholipid components (PE-PEG-Ligand:PE-PEG-Inactivating Moiety:Phospholipid between 0.1:9.9:90 to 5:45:50). This optimization resolves the contradiction by finding the optimal parameter values that achieve high binding efficiency while preventing aggregation
Solution Approach 2:
The patent uses composite materials by creating a stabilizing envelope composed of multiple phospholipid components working together: PE-PEG-Ligand (for cell binding), PE-PEG-Inactivating Moiety (for preventing aggregation), and Phospholipid (for structural integrity). This composite structure allows the microvesicles to simultaneously achieve high ligand density for efficient binding while maintaining stability through the synergistic action of multiple components
2Productivity
If high ligand density is used on microvesicles, then cell separation efficiency improves, but microvesicle destabilization occurs
Solution Approach 1:
The patent applies preliminary anti-action by incorporating an inactivating moiety that preemptively counteracts the harmful effects of high ligand density. The inactivating moiety is designed to prevent the destabilization and aggregation that would otherwise occur at high ligand densities, allowing the microvesicles to maintain reliability while achieving high separation efficiency
Solution Approach 2:
The patent uses an intermediary approach by introducing PE-PEG-Inactivating Moiety as a mediating component that bridges the conflict between high ligand density requirements and stability maintenance. This intermediary component actively works to prevent the adverse effects of high ligand density, enabling the system to achieve both high productivity and reliability
3Adaptability or versatility
If ligand is added to microvesicles, then cell targeting capability increases, but aggregation is promoted
Solution Approach 1:
The patent applies local quality by creating different functional zones within the microvesicle envelope: regions with PE-PEG-Ligand provide cell targeting capability, while regions with PE-PEG-Inactivating Moiety provide anti-aggregation properties. This spatial and functional differentiation allows the microvesicles to simultaneously achieve high adaptability for cell targeting while maintaining suspension stability through locally distributed protective functions
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The formulation achieves stable microvesicles with high ligand density on the surface, enabling efficient cell separation by buoyancy without aggregation, enhancing the effectiveness of buoyancy-activated cell sorting.
Implementation Method 1
buoyancy-activated cell sorting (BACS)... separating cells or biological materials, e.g. by buoyancy
Implementation Method 2
said ligand is capable of selectively binding to biotin. More preferably it is selected from the group consisting of avidin, neutravidin and streptavidin
Implementation Method 3
a stabilizing envelope comprising: a) a phospholipid... The formulation achieves stable microvesicles with high ligand density on the surface
Implementation Method 4
formulations comprising a phospholipid and a suitable mixture of a pegylated phospholipid and of a pegylated phospholipid comprising a ligand may be particularly advantageous
Data Source
AI summary
Formulations of gas-filled microvesicles comprising a ligand, which may advantageously be used in methods for separating cells or biological materials. The formulations comprise a phospholipid and a suitable mixture of a pegylated phospholipid and of a pegylated phospholipid comprising a ligand.